Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
Study Details
Study Description
Brief Summary
This study will determine the highest dose of KW-2450 in combination with lapatinib and letrozole that can be administered safely to subjects with advanced or metastatic breast cancer and to evaluate its effectiveness.
This study was terminated in Phase 1 and never proceeded to the Phase 2 portion of the study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This open-label, sequential, ascending, multi-dose, Phase 1/2 study will enroll up to 198 post-menopausal subjects with advanced or metastatic breast cancer whose tumors overexpress HER2. Subjects at each dose level will receive KW-2450 orally, on a continuous daily schedule in combination with lapatinib and letrozole.
In the Phase 1 portion of the study, dose escalation may proceed once ≥ 3 subjects have completed Day 30. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially. Up to 6 subjects may be enrolled at each dose level. Enrollment will proceed until the MTD has been established or the highest dose level has been reached.
The Phase 2 portion of the trial will enroll 168 additional subjects. The dose level will be based on overall safety and tolerability assessments from the Phase 1 portion of the study. The subjects will be randomized into two treatment arms (1) Arm A, KW-2450 plus lapatinib plus letrozole: (2) Arm B, lapatinib plus letrozole.
This study was terminated in Phase 1 and never proceeded to the Phase 2 portion of the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Dose escallation
|
Drug: KW-2450 in combination with lapatinib and letrozole
Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- To establish the safety, tolerability, and recommended Phase 2 dose of KW-2450 administered in combination with lapatinib and letrozole in subjects with previously treated or untreated advanced breast cancer. [30 Days]
Secondary Outcome Measures
- To determine the PK profile of KW-2450, lapatinib, and letrozole when administered together [1 year (or until PD)]
Eligibility Criteria
Criteria
Inclusion Criteria
-
Histopathologically or cytologically confirmed, advanced or metastatic breast cancer (stage IIIb, IIIc or IV disease) including inflammatory breast cancer or inoperable locally advanced disease.
-
Documented ErbB2 overexpression
-
Estrogen receptor positive (ER+) and/or progesterone positive (PgR+) tumors
-
Measurable or non-measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria
-
A life expectancy of > 3 months for Phase 1 and > 6 months for Phase 2
-
Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2 at study entry in Phase 1 and ≤ 1 in Phase 2;
-
Normal cardiac ejection fraction
-
Adequate hematologic, hepatic and renal function
-
Post-menopausal female (defined as the absence of a menstrual cycle for at least 12 consecutive months) or male subjects ≥ 18 years of age.
-
Sign an IRB or EC approved informed consent
Exclusion Criteria
-
Type 1 diabetes or uncontrolled Type 2 diabetes
-
Subjects showing clinical evidence or with a history of cataract(s), proliferate retinopathy or significant macular edema
-
Subjects with abnormal free T4 values and a history or evidence of thyroid disease
-
Subjects who are unable or unwilling to take metformin
-
Uncontrolled intercurrent illness
-
Known or suspected human immunodeficiency virus (HIV) infection or hepatitis B or C
-
Subjects with inflammatory diseases of the gastrointestinal tract
-
History of other malignancy. Subjects who have been disease free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;
-
Subjects with extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor
-
A history of prior treatment with other agents specifically targeting IGFRs
-
Subjects who require pharmacological doses of glucocorticoids beyond replacement doses. The use of topical, intra-ocular or inhalation glucocorticoids is permitted
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Breastlink Research Group | Long Beach | California | United States | 90250 |
| 2 | Associates in Hematology-Oncology | Los Angeles | California | United States | 90057 |
| 3 | Sylvester Comprehensive Cancer Center | Deerfield Beach | Florida | United States | 33136 |
| 4 | Clinical Oncology Associates | Farmington Hills | Michigan | United States | 48336 |
| 5 | MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- Kyowa Hakko Kirin Pharma, Inc.
Investigators
- Study Director: Michael Kurman, MD, Kyowa Hakko Kirin Pharma, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2450-US-002